Cancer Research AACR Membership  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 236, January 1, 2008. doi: 10.1158/0008-5472.CAN-07-2972
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tan, S.-H.
Right arrow Articles by Nevalainen, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, S.-H.
Right arrow Articles by Nevalainen, M. T.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells

Shyh-Han Tan1, Ayush Dagvadorj1, Feng Shen1, Lei Gu1, Zhiyong Liao1, Junaid Abdulghani1, Ying Zhang2, Edward P. Gelmann3, Tobias Zellweger4, Zoran Culig6, Tapio Visakorpi7, Lukas Bubendorf5, Robert A. Kirken8, James Karras9 and Marja T. Nevalainen1

1 Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; 2 Biostatistics Unit and 3 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; 4 St. Clara Hospital; 5 Institute for Pathology, Basel, Switzerland; 6 Department of Urology, University of Innsbruck, Innsbruck, Austria; 7 Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland; 8 Department of Biological Sciences, University of Texas, El Paso, Texas; and 9 ISIS Pharmaceuticals, Carlsbad, California

Requests for reprints: Marja T. Nevalainen, Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, BLSB 309, Philadelphia, 19107 PA. Phone: 215-503-9250; Fax: 215-503-9245; E-mail: marja.nevalainen{at}jefferson.edu and m_Nevalainen{at}mail.jci.tju.edu.

The molecular mechanisms underlying progression of prostate cancer to the hormone-independent state are poorly understood. Signal transducer and activator of transcription 5a and 5b (Stat5a/b) is critical for the viability of human prostate cancer cells. We have previously shown that Stat5a/b is constitutively active in high-grade human prostate cancer, but not in normal prostate epithelium. Furthermore, activation of Stat5a/b in primary human prostate cancer predicted early disease recurrence. We show here that transcription factor Stat5a/b is active in 95% of clinical hormone-refractory human prostate cancers. We show for the first time that Stat5a/b synergizes with androgen receptor (AR) in prostate cancer cells. Specifically, active Stat5a/b increases transcriptional activity of AR, and AR, in turn, increases transcriptional activity of Stat5a/b. Liganded AR and active Stat5a/b physically interact in prostate cancer cells and, importantly, enhance nuclear localization of each other. The work presented here provides the first evidence of synergy between AR and the prolactin signaling protein Stat5a/b in human prostate cancer cells. [Cancer Res 2008;68(1):236–48]




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
U. Simanainen, K. McNamara, Y. R. Gao, and D. J. Handelsman
Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation
Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1335 - E1343.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. M. Attar, C. H. Takimoto, and M. M. Gottardis
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Clin. Cancer Res., May 15, 2009; 15(10): 3251 - 3255.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. E. Utama, T. H. Tran, A. Ryder, M. J. LeBaron, A. F. Parlow, and H. Rui
Insensitivity of Human Prolactin Receptors to Nonhuman Prolactins: Relevance for Experimental Modeling of Prolactin Receptor-Expressing Human Cells
Endocrinology, April 1, 2009; 150(4): 1782 - 1790.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Dagvadorj, S.-H. Tan, Z. Liao, L. R. Cavalli, B. R. Haddad, and M. T. Nevalainen
Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor
Clin. Cancer Res., October 1, 2008; 14(19): 6062 - 6072.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S.-H. Tan and M. T Nevalainen
Signal transducer and activator of transcription 5A/B in prostate and breast cancers
Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.